Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.creator | Marti-Climent, J.M. (Josep María) | - |
dc.creator | Prieto, E. (Elena) | - |
dc.creator | Moran, V. (Verónica) | - |
dc.creator | Sancho, L. (Lidia) | - |
dc.creator | Rodriguez-Fraile, M. (Macarena) | - |
dc.creator | Arbizu, J. (Javier) | - |
dc.creator | Garcia-Velloso, M. J. (María José) | - |
dc.creator | Richter, J.A. (José Ángel) | - |
dc.date.accessioned | 2024-02-09T10:30:40Z | - |
dc.date.available | 2024-02-09T10:30:40Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Marti-Climent, J.M. (Josep María); Prieto, E. (Elena); Moran, V. (Verónica); et al. "Effective dose estimation for oncological and neurological PET/CT procedures". EJNMMI Research. 7 (1), 2017, 37 | es |
dc.identifier.issn | 2191-219X | - |
dc.identifier.uri | https://hdl.handle.net/10171/68968 | - |
dc.description.abstract | Background: The aim of this study was to retrospectively evaluate the patient effective dose (ED) for different PET/ CT procedures performed with a variety of PET radiopharmaceutical compounds. PET/CT studies of 210 patients were reviewed including Torso (n = 123), Whole body (WB) (n = 36), Head and Neck Tumor (HNT) (n = 10), and Brain (n = 41) protocols with 18FDG (n = 170), 11C-CHOL (n = 10), 18FDOPA (n = 10), 11C-MET (n = 10), and 18F-florbetapir (n = 10). ED was calculated using conversion factors applied to the radiotracer activity and to the CT dose-length product. Results: Total ED (mean ± SD) for Torso-11C-CHOL, Torso-18FDG, WB-18FDG, and HNT-18FDG protocols were 13.5 ± 2.2, 16.5 ± 4.5, 20.0 ± 5.6, and 15.4 ± 2.8 mSv, respectively, where CT represented 77, 62, 69, and 63% of the protocol ED, respectively. For 18FDG, 18FDOPA, 11C-MET, and 18F-florbetapir brain PET/CT studies, ED values (mean ± SD) were 6.4 ± 0.6, 4.6 ± 0.4, 5.2 ± 0.5, and 9.1 ± 0.4 mSv, respectively, and the corresponding CT contributions were 11, 14, 23, and 26%, respectively. In 18FDG PET/CT, variations in scan length and arm position produced significant differences in CT ED (p < 0.01). For dual-time-point imaging, the CT ED (mean ± SD) for the delayed scan was 3.8 ± 1.5 mSv. Conclusions: The mean ED for body and brain PET/CT protocols with different radiopharmaceuticals ranged between 4.6 and 20.0 mSv. The major contributor to total ED for body protocols is CT, whereas for brain studies, it is the PET radiopharmaceutical. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | es_ES |
dc.subject | PET/CT | es_ES |
dc.subject | Effective dose | es_ES |
dc.subject | Radiopharmaceutical | es_ES |
dc.subject | Whole body | es_ES |
dc.title | Effective dose estimation for oncological and neurological PET/CT procedures | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | es_ES |
dc.identifier.doi | 10.1186/s13550-017-0272-5 | - |
dadun.citation.number | 1 | es_ES |
dadun.citation.publicationName | EJNMMI Research | es_ES |
dadun.citation.startingPage | 37 | es_ES |
dadun.citation.volume | 7 | es_ES |
dc.identifier.pmid | 28439843 | - |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.